Related Experiment Video
Updated: Jul 10, 2026

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
CGRP antagonists: unravelling the role of CGRP in migraine
Henri Doods1, Kirsten Arndt, Klaus Rudolf
1Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany. henri.doods@boehringer-ingelheim.com
Abstract:
Migraine is a complex, debilitating neurovascular disorder. Although knowledge on the main molecular players is still incomplete, recent preclinical and clinical findings indicate that there is a clear correlation between migraine-associated headache and the release of the neuropeptide calcitonin gene-related peptide (CGRP). BIBN4096 was the first CGRP antagonist to be tested in clinical trials for the treatment of migraine. The proven efficacy of this agent, and also the CGRP antagonist MK-0974, to alleviate acute migraine headache provided significant support for the hypothesis that CGRP has an important role in migraine pathophysiology. Moreover, the recently published results from Phase II trials are encouraging and suggest that this new type of drug might offer advantages over existing therapies for patients suffering from migraine and related headaches.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Two...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Acting on Autonomic Ganglia: Blockers
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

